Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.43 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005444 | 1.00 | GAA (0.46) | GAANPY5RNPY2RSLC6A9ALDH1A1 | |
| SCHEMBL13764880 | 0.87 | GAA (0.51) | GAANPY5RNPY2RSLC6A9ALDH1A1 | |
| SCHEMBL13769307 | 0.83 | GAA (0.56) | GAANPY5RNPY2RALDH1A1KDM4E | |
| SCHEMBL4006717 | 0.82 | GAA (0.46) | GAANPY5RNPY2RSLC6A9ALDH1A1 | |
| SCHEMBL13764895 | 0.82 | GAA (0.46) | GAANPY5RNPY2RSLC6A9ALDH1A1 | |
| SCHEMBL3999333 | 0.81 | GAA (0.45) | GAANPY5RNPY2RSLC6A9ALDH1A1 | |
| SCHEMBL4000089 | 0.77 | GAA (0.41) | GAANPY5RNPY2R | |
| SCHEMBL16597152 | 0.76 | GAA (0.55) | GAANPY5RALDH1A1KDM4E | |
| SCHEMBL13764906 | 0.76 | GAA (0.55) | GAANPY5RALDH1A1KDM4E | |
| SCHEMBL4004397 | 0.75 | MMP1 (0.40) | ALDH1A1CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563888-B2 | Process for the preparation of diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7563888-B2 | Process for the preparation of diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-20070149501-A1 | PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149501-A1 | PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149501-A1 | PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES | CYP46A1, APOB, DHCR7 | GAA 1290/4885NPY5R 714/4885NPY2R 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.